Indaptus Therapeutics Q1 net loss narrows as expenses fall

Indaptus Therapeutics Inc

Indaptus Therapeutics Inc

INDP

0.00


Overview

  • U.S. biotech firm's Q1 net loss narrowed as operating expenses declined

  • Company is reassessing development priorities after executive management transition

  • Cash and cash equivalents fell to $1.5 mln; company says more funding will be needed


Outlook

  • Company is reassessing development priorities and resource allocation following management changes

  • Indaptus continues to evaluate corporate initiatives and potential development opportunities

  • Company is assessing financing alternatives and strategic options to support its corporate strategy


Result Drivers

  • LOWER CLINICAL COSTS - Co said research and development expenses fell mainly due to decreased clinical costs related to its Phase 1 study

  • MANAGEMENT TRANSITION - Co cited recent executive management changes and ongoing operational and organizational adjustments

  • STRATEGIC REVIEW - Co is reassessing development priorities, operating initiatives and resource allocation as part of a broader review


Company press release: ID:nGNX7qJrZV


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

-$0.23


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.